儿童原发免疫性血小板减少症miR-106b-5p的表达及其与T细胞的相关性研究

doi:10.7499/j.issn.1008-8830.2110139

摘要
图/表
参考文献(17)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (643 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的探讨血浆miR-106b-5p在原发免疫性血小板减少症（primary immune thrombocytopenia，ITP）中的表达及其与辅助性T细胞17（T helper cells 17，Th17）、调节性T细胞（T regulatory cell，Treg）、Th17/Treg的相关性。方法选取79例ITP患儿（ITP组）和40例健康儿童（对照组）为研究对象。79例ITP患儿根据治疗效果分为完全有效组（40例）、有效组（18例）、无效组（21例）。采用实时荧光定量PCR技术检测miR-106b-5p表达水平，流式细胞技术检测Th17和Treg，计算Th17/Treg，分析血浆miR-106b-5p表达水平与Th17、Treg及Th17/Treg的相关性。结果 ITP组miR-106b-5p、Th17及Th17/Treg水平高于对照组（P<0.05），Treg水平低于对照组（P<0.05）。ITP组患儿治疗后miR-106b-5p、Th17、Th17/Treg水平低于治疗前（P<0.05），Treg水平高于治疗前（P<0.05）。完全有效组miR-106b-5p、Th17、Th17/Treg水平低于有效组和无效组（P<0.05），Treg水平高于有效组和无效组（P<0.05）。相关分析显示，ITP患儿血浆miR-106b-5p表达水平与Th17、Th17/Treg均呈正相关（分别r=0.730、0.816，均P<0.001），与Treg呈负相关（r=-0.774，P<0.001）。结论 ITP患儿存在miR-106b-5p高表达和Th17/Treg比例失衡，在ITP患儿治疗过程中检测miR-106b-5p、Th17、Treg及Th17/Treg水平，对ITP患儿的疗效判断具有较好的指导作用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王文芳
	王绪松
	谭三阳
	钟兰兰
	陈江

关键词 ：原发免疫性血小板减少症, miR-106b-5p, 辅助性T细胞17, 调节性T细胞, 儿童

Abstract：Objective To study the expression level of plasma miR-106b-5p in primary immune thrombocytopenia (ITP) and its correlation with the levels of T helper 17 cell (Th17) and regulatory T cell (Treg) and the Th17/Treg ratio. Methods A total of 79 children with ITP (ITP group) and 40 healthy children (control group) were selected as subjects. According to the treatment response, the 79 children with ITP were divided into three groups: complete response (n=40), partial response (n=18), and non-response (n=21). Quantitative real-time PCR was used to measure the expression level of miR-106b-5p. Flow cytometry was used to measure the frequencies of Th17 and Treg, and the Th17/Treg ratio was calculated. The correlation of the expression level of plasma miR-106b-5p with the frequencies of Th17 and Treg and the Th17/Treg ratio was analyzed. Results Compared with the control group, the ITP group had significantly higher levels of miR-106b-5p, Th17, and Th17/Treg ratio (P<0.05) and a significantly lower level of Treg (P<0.05). After treatment, the ITP group had significant reductions in the levels of miR-106b-5p, Th17, and Th17/Treg ratio (P<0.05) and a significant increase in the level of Treg (P<0.05). Compared with the partial response and non-response groups, the complete response group had significantly lower levels of miR-106b-5p, Th17, and Th17/Treg ratio (P<0.05) and a significantly higher level of Treg (P<0.05). The correlation analysis showed that in the children with ITP, the expression level of plasma miR-106b-5p was positively correlated with the Th17 level and the Th17/Treg ratio (r=0.730 and 0.816 respectively; P<0.001) and was negatively correlated with the Treg level (r=-0.774, P<0.001). Conclusions A higher expression level of miR-106b-5p and Th17/Treg imbalance may be observed in children with ITP. The measurement of miR-106b-5p, Th17, Treg, and Th17/Treg ratio during treatment may be useful to the evaluation of treatment outcome in children with ITP.

Key words： Primary immune thrombocytopenia miR-106b-5p T helper 17 cell Regulatory T cell Child

收稿日期: 2021-10-30

通讯作者: 陈江，男，副主任医师。Email：904829078@qq.com。 E-mail: 904829078@qq.com

作者简介: 王文芳，女，本科，主管检验技；

引用本文:

王文芳,王绪松,谭三阳等. 儿童原发免疫性血小板减少症miR-106b-5p的表达及其与T细胞的相关性研究[J]. 中国当代儿科杂志, 2022, 24(4): 411-416.

WANG Wen-Fang,WANG Xu-Song,TAN San-Yang et al. Expression of miR-106b-5p in children with primary immune thrombocytopenia and its correlation with T cells[J]. CJCP, 2022, 24(4): 411-416.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2110139 或 http://www.zgddek.com/CN/Y2022/V24/I4/411

	Grainger JD, Kühne T, Hippenmeyer J, et al. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia[J]. Ann Hematol, 2021, 100(9): 2143-2154. PMID: 34308495. PMCID: PMC8310729. DOI: 10.1007/s00277-021-04590-0.
	Elnaenaey WA, Omar OM, Aboelwafa RA. Increased expression of IL-17A and IL-17F is correlated with RUNX1 and RORγT in pediatric patients with primary immune thrombocytopenia[J]. J Pediatr Hematol Oncol, 2021, 43(3): e320-e327. PMID: 33633027. DOI: 10.1097/MPH.0000000000002108.
	Gu H, Chen ZP, Shi XD, et al. Increased proportion of Th17/Treg cells at the new diagnosed stage of chronic immune thrombocytopenia in pediatrics: the pilot study from a multi-center[J]. Eur J Pediatr, 2021, 180(11): 3411-3417. PMID: 34046719. DOI: 10.1007/s00431-021-04121-z.
	Li QZ, Liu Y, Wang XJ, et al. Regulation of Th1/Th2 and Th17/Treg by pDC/mDC imbalance in primary immune thrombocytopenia[J]. Exp Biol Med (Maywood), 2021, 246(15): 1688-1697. PMID: 33938255. DOI: 10.1177/15353702211009787.
	Wang SC, Yang KD, Lin CY, et al. Intravenous immunoglobulin therapy enhances suppressive regulatory T cells and decreases innate lymphoid cells in children with immune thrombocytopenia[J]. Pediatr Blood Cancer, 2020, 67(2): e28075. PMID: 31736241. DOI: 10.1002/pbc.28075.
	Atabaki M, Shariati-Sarabi Z, Barati M, et al. MicroRNAs as the important regulators of T helper 17 cells: a narrative review[J]. Iran J Allergy Asthma Immunol, 2020, 19(6): 589-601. PMID: 33463128. DOI: 10.18502/ijaai.v19i6.4928.
	Sun YQ, Hou Y, Meng GY, et al. Proteomic analysis and microRNA expression profiling of plasma-derived exosomes in primary immune thrombocytopenia[J]. Br J Haematol, 2021, 194(6): 1045-1052. PMID: 34337736. DOI: 10.1111/bjh.17720.
	Hua MQ, Li J, Wang CY, et al. Aberrant expression of microRNA in CD4+ cells contributes to Th17/Treg imbalance in primary immune thrombocytopenia[J]. Thromb Res, 2019, 177: 70-78. PMID: 30856381. DOI: 10.1016/j.thromres.2019.03.005.
	Eroglu F, Dokur M, Ulu Y. MicroRNA profile in immune response of alveolar and cystic echinococcosis patients[J]. Parasite Immunol, 2021, 43(7): e12817. PMID: 33410199. DOI: 10.1111/pim.12817.
	中国儿童原发性免疫性血小板减少症诊断与治疗指南改编工作组, 中华医学会儿科学分会血液学组, 中华儿科杂志编辑委员会. 中国儿童原发性免疫性血小板减少症诊断与治疗改编指南(2021版)[J]. 中华儿科杂志, 2021, 59(10): 810-819. PMID: 34587675. DOI: 10.3760/cma.j.cn112140-20210509-00397.
	Singh G, Bansal D, Wright NAM. Immune thrombocytopenia in children: consensus and controversies[J]. Indian J Pediatr, 2020, 87(2): 150-157. PMID: 31927692. DOI: 10.1007/s12098-019-03155-4.
	Li JQ, Tian JM, Fan XR, et al. miR-106b-5p induces immune imbalance of Treg/Th17 in immune thrombocytopenic purpura through NR4A3/Foxp3 pathway[J]. Cell Cycle, 2020, 19(11): 1265-1274. PMID: 32323598. PMCID: PMC7469554. DOI: 10.1080/15384101.2020.1746485.
	Qian C, Yan WY, Li TD, et al. Differential expression of miR-106b-5p and miR-200c-3p in newly diagnosed versus chronic primary immune thrombocytopenia patients based on systematic analysis[J]. Cell Physiol Biochem, 2018, 45(1): 301-318. PMID: 29402802. DOI: 10.1159/000486811.
	He Y, Ji DX, Lu W, et al. Bone marrow mesenchymal stem cell-derived exosomes induce the Th17/Treg imbalance in immune thrombocytopenia through miR-146a-5p/IRAK1 axis[J]. Hum Cell, 2021, 34(5): 1360-1374. PMID: 34052997. DOI: 10.1007/s13577-021-00547-7.
	Jafarzadeh A, Marzban H, Nemati M, et al. Dysregulated expression of miRNAs in immune thrombocytopenia[J]. Epigenomics, 2021, 13(16): 1315-1325. PMID: 34498489. DOI: 10.2217/epi-2021-0092.
	Cheng LY, Liu CJ, Li F, et al. The prediction value of Treg cell subtype alterations for glucocorticoid treatment in newly diagnosed primary immune thrombocytopenia patients[J]. Thromb Res, 2019, 181: 10-16. PMID: 31323447. DOI: 10.1016/j.thromres.2019.07.001.
	Zhu YD, Zhu H, Xie XB, et al. MicroRNA expression profile in Treg cells in the course of primary immune thrombocytopenia[J]. J Investig Med, 2019, 67(8): 1118-1124. PMID: 31273052. PMCID: PMC6900216. DOI: 10.1136/jim-2019-001020.